170 related articles for article (PubMed ID: 29137877)
1. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.
Kim JW; Shin MS; Kang Y; Kang I; Petrylak DP
Clin Genitourin Cancer; 2018 Apr; 16(2):e469-e476. PubMed ID: 29137877
[TBL] [Abstract][Full Text] [Related]
2. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Saylor PJ; Kozin SV; Matsui A; Goldberg SI; Aoki S; Shigeta K; Mamessier E; Smith MR; Michaelson MD; Lee RJ; Duda DG
Radiother Oncol; 2024 Mar; 192():110091. PubMed ID: 38224917
[TBL] [Abstract][Full Text] [Related]
3. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Yap KK; Wong W; Ji L; Groshen S; Quinn DI; Bryce AH; Dorff TB
Cancer Treat Res Commun; 2019; 18():100114. PubMed ID: 30529990
[TBL] [Abstract][Full Text] [Related]
4. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
5. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D; Hatakeyama S; Kawaguchi H; Hatayama Y; Ishibashi Y; Kusaka A; Noro D; Tanaka T; Ito H; Okuyama Y; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Aoki M; Ohyama C
Urol Oncol; 2022 Feb; 40(2):64.e1-64.e8. PubMed ID: 34973857
[TBL] [Abstract][Full Text] [Related]
6. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
7. Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Caffo O; Frantellizzi V; Monari F; Sbrana A; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Palermo A; Fanti S; Biasco E; Murabito A; Filice A; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; Cortesi E; Vincentis G
Future Oncol; 2021 Mar; 17(7):807-815. PubMed ID: 33508980
[No Abstract] [Full Text] [Related]
8. Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Choudhury AD; Kwak L; Cheung A; Allaire KM; Marquez J; Yang DD; Tripathi A; Kilar JM; Flynn M; Maynard B; Reichel R; Pace AF; Chen BK; Van Allen EM; Kilbridge K; Wei XX; McGregor BA; Pomerantz MM; Bhatt RS; Sweeney CJ; Bubley GJ; Jacene HA; Taplin ME; Huang FW; Harshman LC; Fong L
Cancer Immunol Res; 2024 Jun; 12(6):704-718. PubMed ID: 38552171
[TBL] [Abstract][Full Text] [Related]
9. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
11. DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
Ramos JD; Mostaghel EA; Pritchard CC; Yu EY
Clin Genitourin Cancer; 2018 Apr; 16(2):106-110. PubMed ID: 29287968
[No Abstract] [Full Text] [Related]
12. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
13. Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223.
Poon DMC; Wong KCW
Clin Genitourin Cancer; 2018 Apr; 16(2):e397-e401. PubMed ID: 29174502
[No Abstract] [Full Text] [Related]
14. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.
Suominen MI; Fagerlund KM; Rissanen JP; Konkol YM; Morko JP; Peng Z; Alhoniemi EJ; Laine SK; Corey E; Mumberg D; Ziegelbauer K; Käkönen SM; Halleen JM; Vessella RL; Scholz A
Clin Cancer Res; 2017 Aug; 23(15):4335-4346. PubMed ID: 28364014
[No Abstract] [Full Text] [Related]
15. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
16. Effect of human bone marrow mesenchymal stromal cells on cytokine production by peripheral blood naive, memory, and effector T cells.
Laranjeira P; Pedrosa M; Pedreiro S; Gomes J; Martinho A; Antunes B; Ribeiro T; Santos F; Trindade H; Paiva A
Stem Cell Res Ther; 2015 Jan; 6(1):3. PubMed ID: 25559824
[TBL] [Abstract][Full Text] [Related]
17. Radium 223 dichloride for prostate cancer treatment.
Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
19. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
20. Radium-223 international early access program: results from the Spanish subset.
Carles J; Méndez MJ; Pinto Á; Sáez MI; Arranz JA; Maroto P; López-Criado P; Mellado B; Donas JG; Hernando S; León L; Del Alba AG; Laínez N; Esteban E; Reynés G; Pérez-Gracia JL; Germà JR; López-Brea M; Pérez-Valderrama B; Moretones C; Castellano D
Future Oncol; 2018 Jan; 14(1):41-50. PubMed ID: 29232987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
